FDA approves an Ebola vaccine, long in development, for the first time – STAT
The vaccine, developed by Merck, protects against Zaire ebolaviruses, the species of the virus that has been the most common cause of Ebola outbreaks.
Related Articles
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
Sickle cell disease is a life-threatening haematological condition described as the most neglected global health problem today. There are enough data to show the enormous…
Bone marrow transplantation for sickle cell disease improves myocardial fibrosis
Learn about St. Jude research showing that bone marrow transplantation to treat sickle cell disease can improve heart damage such as myocardial fibrosis.
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
Sickle cell disease is a life-threatening haematological condition described as the most neglected global health problem today. There are enough data to show the enormous…
Tandem Thursday Breakfast Symposium: The Evolving Paradigm of Sickle Cell Disease Management
The paradigm of sickle cell disease management is rapidly evolving with exciting new advances in transplant and genetic therapies. Are you ready for these changes?…
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.